Patents by Inventor David Arthur Berry

David Arthur Berry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS
    Publication number: 20210244774
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 12, 2021
    Applicant: Seres Therapeutics, Inc,
    Inventors: Gregory MCKENZIE, Mary-Jane LOMBARDO MCKENZIE, David N. COOK, Marin VULIC, Geoffrey VON MALTZAHN, Brian GOODMAN, John Grant AUNINS, Matthew R. HENN, David Arthur BERRY, Jonathan WINKLER
  • Acylated active agents and methods of their use for the treatment of autoimmune disorders
    Patent number: 11058698
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20210177877
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Application
    Filed: November 17, 2020
    Publication date: June 17, 2021
    Inventors: Steven John TAYLOR, John Robert PROUDFOOT, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Afrand KAMALI SARVESTANI, Leonard BUCKBINDER, Bernard LANTER, Ferdinand Edward MASSARI, Koji YASUDA, Spencer Cory PECK, Cheri SNEDEKER, Diana LE, Jessica ALEXANDER, Anna LIANG, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • Synergistic Bacterial Compositions and Methods of Production and Use Thereof
    Publication number: 20210169949
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: December 14, 2020
    Publication date: June 10, 2021
    Applicant: Seres Therapeutics, Inc,
    Inventors: Matthew R. HENN, Geoffrey von MALTZAHN, Anthony Mario D'ONOFRIO, Kevin Daniel LITCOFSKY, David Arthur BERRY, David N. COOK, Noubar B. AFEYAN, John Grant AUNINS
  • Synergistic Bacterial Compositions and Methods of Production and Use Thereof
    Publication number: 20210169948
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: December 14, 2020
    Publication date: June 10, 2021
    Applicant: Seres Therapeutics, Inc,
    Inventors: Matthew R. HENN, Geoffrey von MALTZAHN, Anthony Mario D'ONOFRIO, Kevin Daniel LITCOFSKY, David Arthur BERRY, David N. COOK, Noubar B. AFEYAN, John Grant AUNINS
  • Synergistic Bacterial Compositions and Methods of Production and Use Thereof
    Publication number: 20210169946
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: December 14, 2020
    Publication date: June 10, 2021
    Applicant: Seres Therapeutics, Inc,
    Inventors: Matthew R. HENN, Geoffrey von MALTZAHN, Anthony Mario D'ONOFRIO, Kevin Daniel LITCOFSKY, David Arthur BERRY, David N. COOK, Noubar B. AFEYAN, John Grant AUNINS
  • Synergistic Bacterial Compositions and Methods of Production and Use Thereof
    Publication number: 20210169947
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: December 14, 2020
    Publication date: June 10, 2021
    Applicant: Seres Therapeutics, Inc,
    Inventors: Matthew R. HENN, Geoffrey von MALTZAHN, Anthony Mario D'ONOFRIO, Kevin Daniel LITCOFSKY, David Arthur BERRY, David N. COOK, Noubar B. AFEYAN, John Grant AUNINS
  • CONJUGATES AND METHODS OF USING THE SAME
    Publication number: 20210162057
    Abstract: Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 3, 2021
    Inventors: Spencer Cory PECK, Steven John TAYLOR, Elijah Lane BOGART, Devin Forest Reed DOUD, Joo Hyun IM, Dervla Tamara ISAAC, Jenny LIU, Ferdinand Edward MASSARI, Robert Walter MYERS, John Robert PROUDFOOT, Cheri Ross, John Patrick CASEY, JR., David Arthur BERRY
  • Compositions and methods
    Patent number: 10967011
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: April 6, 2021
    Assignee: Seres Therapeutics, Inc.
    Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
  • ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20210085640
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating a cancer marker or for treating cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: March 25, 2021
    Inventors: Steven John TAYLOR, Leonard BUCKBINDER, John Robert PROUDFOOT, Mi-Jeong KIM, Timothy F. BRIGGS, Ferdinand Edward MASSARI, Spencer Cory PECK, Koji YASUDA, Amir MOAREFI, David Arthur BERRY, John Patrick CASEY, JR.
  • Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
    Patent number: 10953027
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 23, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • METHODS AND COMPOSITIONS FOR MODULATING THYMIC FUNCTION
    Publication number: 20210000921
    Abstract: The invention described herein features methods and compositions for modifying thymic function and/or activity in a subject (e.g., a human, e.g., a human patient in need thereof; or a non-human animal, e.g., a companion animal or an agricultural animal).
    Type: Application
    Filed: January 11, 2017
    Publication date: January 7, 2021
    Inventors: David Arthur Berry, Alexander Nichols, Douglas Ewen Cameron, Brett Blackman, Chantal Kuhn
  • Network-based microbial compositions and methods
    Patent number: 10881696
    Abstract: Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: January 5, 2021
    Assignee: Seres Therapeutics, Inc.
    Inventors: Matthew R. Henn, David N. Cook, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Kevin D. Litcofsky, Han Zhang, John Grant Aunins, David Arthur Berry
  • Compositions and Formulations and Methods of Production and Use Thereof
    Publication number: 20200405807
    Abstract: Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.
    Type: Application
    Filed: July 1, 2020
    Publication date: December 31, 2020
    Inventors: Alison Williams, Nathaniel W. Silver, Andrew Downey, David V. Erbe, Michael J. Hamill, David Arthur Berry
  • Synergistic bacterial compositions and methods of production and use thereof
    Patent number: 10864235
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 15, 2020
    Assignee: Seres Therapeutics, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David Arthur Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Synergistic Bacterial Compositions and Methods of Production and Use Thereof
    Publication number: 20200345792
    Abstract: Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 5, 2020
    Applicant: SERES THERAPEUTICS, INC.
    Inventors: Matthew R. Henn, Kevin Daniel Litcofsky, Anthony Mario D'Onofrio, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Geoffrey von Maltzahn, David N. Cook, David Arthur Berry, Noubar B. Afeyan, John Grant Aunins
  • ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20200197428
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 25, 2020
    Inventors: Steven John TAYLOR, John Robert PROUDFOOT, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Afrand KAMALI SARVESTANI, Leonard BUCKBINDER, Bernard LANTER, Ferdinand Edward MASSARI, Koji YASUDA, Spencer Cory PECK, Cheri SNEDEKER, Diana LE, Jessica ALEXANDER, Anna LIANG, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20200188418
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 18, 2020
    Inventors: Steven John TAYLOR, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Koji YASUDA, Leonard BUCKBINDER, Bernard LANTER, Spencer Cory PECK, Cheri SNEDEKER, Angela SHE, Jessica ALEXANDER, Anna LIANG, Jenny LIU, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • Charged Nutritive Proteins and Methods
    Publication number: 20200109175
    Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.
    Type: Application
    Filed: September 10, 2019
    Publication date: April 9, 2020
    Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Michael Hamill, Rajeev Chillakuru, John F. Kramarczyk
  • MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME
    Publication number: 20200101030
    Abstract: Multibiotic agents are disclosed. The multibiotic agents may contain two or more moieties linked through bonds cleavable in vivo. The bonds cleavable in vivo can be ester bonds, amide bonds, azo bonds, glycosidic bonds, carbonate linkers, or carbamate linkers. The moieties can be alcohol cores, amine cores, and/or acyls. Also disclosed are compositions containing multibiotic agents and methods of using the multibiotic agents.
    Type: Application
    Filed: December 3, 2019
    Publication date: April 2, 2020
    Inventors: John Patrick CASEY, JR., David Arthur BERRY, Alfredo CASTRO, Steven John TAYLOR, Ferdinand Edward MASSARI, John Robert PROUDFOOT, Elijah Lane BOGART, Timothy F. BRIGGS